sellWeak
Novo Holdings A/S sold $99k of IOBT
owner at IO Biotech, Inc.. 75,000 shares at an average of $1.32, traded Jul 25, 2024, filed Jul 26, 2024.
Warning score
22Value
$99k
75,000 shares
Holdings after
4,354,449
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +10Trade size$99k at market
- 0Share of holdings soldSold 1.7% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-087061, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | SOpen-market sale COMMON STOCK | -51,522 | $1.33 | $68k | 4,377,927 | Jul 26, 2024 |
| Jul 26, 2024 | SOpen-market sale COMMON STOCK | -23,478 | $1.31 | $31k | 4,354,449 | Jul 26, 2024 |
Related signals
Other insiders at IO Biotech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | IOBTbuy IO Biotech, Inc. | Heidi Hunter director | $21k 15,000 shares | - | |
| 43Moderate | IO Biotech, Inc. | Qasim Iftikhar Ahmad Chief Medical Officer | $27k 31,350 shares | - | |
| 40Moderate | IO Biotech, Inc. | Devin Whittemore Smith General Counsel | $9,720 12,000 shares | +243% | |
| 40Moderate | IO Biotech, Inc. | Amy Sullivan Chief Financial Officer | $8,483 10,250 shares | +14% | |
| 46Moderate | IO Biotech, Inc. | Mai-Britt Zocca Chief Executive Officer | $10k 12,500 shares | +33% | |
| 39Weak | IOBTsell IO Biotech, Inc. | Novo Holdings A/S owner | $802k 658,809 shares | -13% | |
| 42Moderate | IOBTsell IO Biotech, Inc. | Novo Holdings A/S owner | $988k 658,809 shares | -11% | |
| 25Weak | IOBTbuy IO Biotech, Inc. | Brian Burkavage Chief Accounting Officer | $10k 10,000 shares | +667% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.